<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1210211157
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LYRGABA 150 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PREGABALIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        110.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="(Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            (Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 437]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lyrgaba belongs to a group of medicines used to treat epilepsy, neuropathic pain and Generalised Anxiety Disorder (GAD) in adults.</p><p><strong>Peripheral</strong><strong> and central neuropathic pain: </strong>Lyrgaba is used to treat long lasting pain caused by damage to the nerves. A variety of diseases can cause peripheral neuropathic pain, such as diabetes or shingles. Pain sensations may be described as hot, burning, throbbing, shooting, stabbing, sharp, cramping,</p><p>aching, tingling, numbness, pins and needles. Peripheral and central neuropathic pain may also be associated with mood changes, sleep disturbance, fatigue (tiredness), and can have an impact on physical and social functioning and overall quality of life.</p><p><strong>Epilepsy:</strong><strong> </strong>Lyrgaba is used to treat a certain form of epilepsy (partial seizures with or without secondary generalization) in adults. Your doctor will prescribe Lyrgaba for you to help treat your epilepsy when your current treatment is not controlling your condition. You should take Lyrgaba in addition to your current treatment. Lyrgaba is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment.</p><p><strong>Generalized</strong><strong> </strong><strong>Anxiety</strong><strong> </strong><strong>Disorder:</strong><strong> </strong>Lyrgaba is used to treat Generalized Anxiety Disorder (GAD). The</p><p>symptoms of GAD are prolonged excessive anxiety and worry that are difficult to control. GAD can also cause restless- ness or feeling keyed up or on edge, being easily fatigued (tired), having difficulty</p><p>concentrating or mind going blank, feeling irritable, having muscle tension or sleep disturbance. This is different to the stresses and strains of everyday life.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Lyrgaba:</p><p>If you are allergic (Hypertensive) to pregabalin or any of the other ingredients of this medicine.</p><p>Warnings and Precautions</p><p>Talk to your doctor or pharmacist before taking Lyrgaba.</p><p>&bull; Some patients taking Lyrgaba have reported symptoms suggesting an allergic reaction. These symptoms include swelling of the face, lips, tongue, and throat, as well as diffuse skin rash. If you experience any of these reactions, you should contact your physician immediately.</p><p>&bull; Lyrgaba has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in elderly patients. Therefore, you should be careful until you are used to any effect the medicine might have.</p><p>&bull; Lyrgaba may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary. You should immediately tell your doctor if you experience any changes in your vision.</p><p>&bull; Some patients with diabetes who gain weight while taking pregabalin may need an alteration in their diabetic medicines.</p><p>&bull; Certain side effects may be more common, such as sleepiness, because patients with spinal cord injury may be taking other medicines to treat, for example, pain or spasticity, that have similar side effects to Pregabalin and the severity of these effects may be increased when taken together.</p><p>&bull; There have been reports of heart failure in some patients when taking Lyrgaba; these patients were mostly elderly with cardiovascular conditions. <strong>Before taking this medicine, you should tell your doctor if you have a history of</strong><strong> </strong><strong>heart disease.</strong></p><p>&bull; Severe breathing problems have happened. Sometimes, this has been deadly. The risk may be greater in people taking certain drugs like opioid pain drugs and other central nervous system (CNS) depressants or those with certain health problems like chronic obstructive pulmonary disease (COPD). The risk may also be greater in people who are older than 65. If you have questions, talk with the doctor.</p><p>&bull; There have been reports of kidney failure in some patients when taking Lyrgaba. If while taking Lyrgaba you notice decreased urination, you should tell your doctor as stopping the medicine may improve this.</p><p>&bull; A small number of people being treated with anti-epileptics such as Lyrgaba have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.</p><p>&bull; When Lyrgaba is taken with other medicines that may cause constipation (such as some types of pain medicines) it is possible that gastrointestinal problems may occur (e.g. constipation, blocked or paralyses bowel). Tell your doctor if you experience constipation, especially if you are prone to this problem.</p><p>&bull; Before taking this medicine, you should tell your doctor if you have a history of alcoholism or any drug abuse or dependence. Do not take more medicine than prescribed.</p><p>&bull; There have been reports of convulsions when taking Lyrgaba or shortly after stopping Lyrgaba. If you experience a convulsion, contact your doctor immediately.</p><p>&bull; There have been reports of reduction in brain function (encephalopathy) in some patients taking Lyrgaba when they have other conditions. Tell your doctor if you have a history of any serious medical conditions, including liver or kidney disease.</p><p>Children and adolescents</p><p>The safety and efficacy in children and adolescents (under 18 years of age) has not been established and therefore, pregabalin should not be used in this age group.</p><p>Other medicines and Lyrgaba</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Lyrgaba and certain other medicines may influence each other (interaction). When taken with certain other medicines, Lyrgaba may potentiate the side effects seen with these medicines, including respiratory failure and coma. The degree of dizziness, sleepiness and decreased concentration may be increased if Lyrgaba is taken together with medicines containing:</p><p>Oxycodone &ndash; (used as a pain-killer), Lorazepam &ndash; (used for treating anxiety), Alcohol</p><p>Opioids and CNS depressants</p><p>Monitor for symptoms of respiratory depression and sedation if you are taking opioids or CNS depressants such as benzodiazepine.</p><p>Lyrgaba may be taken with oral contraceptives.</p><p>Lyrgaba with food, drink and alcohol</p><p>Lyrgaba capsules may be taken with or without food. It is advised not to drink alcohol while taking Lyrgaba.</p><p>Pregnancy and breast-feeding</p><p>Lyrgaba should not be taken during pregnancy or when breast-feeding, unless you are told otherwise by your doctor. Ef- fective contraception must be used by women of child-bearing potential. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. <strong>Driving and using machines</strong></p><p>Lyrgaba may produce dizziness, sleepiness and decreased concentration. You should not drive, operate complex machinery or engage in other potentially hazardous activities until you know whether this medicine affects your ability to perform these activities.</p><p>Lyrgaba contains lactose monohydrate</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will determine what dose is appropriate for you. Lyrgaba is for oral use only.</p><p>Peripheral and central neuropathic pain, epilepsy or Generalized Anxiety Disorder:</p><p>&bull; Take the number of capsules as instructed by your doctor.</p><p>&bull; The dose, which has been adjusted for you and your condition, will generally be between 150 mg and 600 mg each day.</p><p>&bull; Your doctor will tell you to take Lyrgaba either twice or three times a day. For twice a day take Lyrgaba once in the morning and once in the evening, at about the same time each day. For three times, a day take</p><p>Lyrgaba once in the morning, once in the afternoon and once in the evening, at about the same time each day.</p><p>If you have the impression that the effect of Lyrgaba is too strong or too weak, talk to your doctor or pharmacist.</p><p>If you are an elderly patient (over 65 years of age), you should take Lyrgaba normally except if you have problems with your kidneys.</p><p>Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys. Swallow the capsule whole with water.</p><p>Continue taking Lyrgaba until your doctor tells you to stop.</p><p>If you take more Lyrgaba than you should</p><p>Call your doctor or go to the nearest hospital emergency unit immediately. Take your box or bottle of Lyrgaba capsules with you. You may feel sleepy, confused, agitated, or restless as a result of taking more Lyrgaba than you should. Fits have also been reported.</p><p>If you forget to take Lyrgaba</p><p>It is important to take your Lyrgaba capsules regularly at the same time each day. If you forget to take a dose, take it as soon as you remember unless it is time for your next dose. In that case, just carry on with the next dose as normal. Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Lyrgaba</p><p>Do not stop taking Lyrgaba unless your doctor tells you to. If your treatment is stopped it should be done gradually over a minimum of 1 week.</p><p>After stopping long and short-term Lyrgaba treatment, you need to know that you may experience certain side effects.</p><p>These include, trouble sleeping, headache, nausea, feeling anxious, diarrhea, flu- like symptoms, convulsions, nervousness, depression, pain, sweating, and dizziness. These symptoms may occur more commonly or severely if you have been taking Lyrgaba for a longer period of time.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Very common: may affect more than 1 in 10 people</p><p>Dizziness, drowsiness, headache.</p><p>Common: may affect up to 1 in 10 people</p><p>&bull; Increased appetite.</p><p>&bull; Feeling of elation, confusion, disorientation, decrease in sexual interest, irritability.</p><p>&bull; Disturbance in attention, clumsiness, memory impairment, loss of memory, tremor, difficulty with speaking, tingling feeling, numbness, sedation, lethargy, insomnia, fatigue, feeling abnormal.</p><p>&bull; Blurred vision, double vision.</p><p>&bull; Vertigo, problems with balance, fall.</p><p>&bull; Dry mouth, constipation, vomiting, flatulence, diarrhea, nausea, swollen abdomen.</p><p>&bull; Difficulties with erection.</p><p>&bull; Swelling of the body including extremities.</p><p>&bull; Feeling drunk, abnormal style of walking.</p><p>&bull; Weight gain.</p><p>&bull; Muscle cramp, joint pain, back pain, pain in limb.</p><p>&bull; Sore throat.</p><p>Uncommon: may affect up to 1 in 100 people</p><p>&bull; Loss of appetite, weight loss, low blood sugar, high blood sugar.</p><p>&bull; Change in perception of self, restlessness, depression, agitation, mood swings, difficulty finding words, hallucinations, abnormal dreams, panic attack, apathy, aggression, elevated mood, mental impairment,</p><p>difficulty with thinking, increase in sexual interest, problems with sexual functioning including inability to achieve a sexual climax, delayed ejaculation.</p><p>&bull; Changes in eyesight, unusual eye movement, changes in vision including tunnel vision, flashes of light, jerky movements, reduced reflexes, increased activity, dizziness on standing, sensitive skin, loss of taste, burning sensation, tremor on movement, decreased consciousness, loss of consciousness, fainting, increased sensitivity to noise, feeling unwell.</p><p>&bull; Dry eyes, eye swelling, eye pain, weak eyes, watery eyes, eye irritation.</p><p>&bull; Heart rhythm disturbances, increased heart rate, low blood pressure, high blood pressure, changes in heartbeat, heart failure.</p><p>&bull; Flushing, hot flushes.</p><p>&bull; Difficulty breathing, dry nose, nasal congestion.</p><p>&bull; Increased saliva production, heartburn, numb around mouth.</p><p>&bull; Sweating, rash, chills, fever.</p><p>&bull; Muscle twitching, joint swelling, muscle stiffness, pain including muscle pain, neck pain.</p><p>&bull; Breast pain.</p><p>&bull; Difficulty with or painful urination, incontinence.</p><p>&bull; Weakness, thirst, chest tightness.</p><p>&bull; Changes in blood and liver test results (blood creatinine phosphokinase increased, alanine amino</p><p>transferase increased, aspartate aminotransferase increased, platelet count decreased, neutropenia, increase in blood creatinine, decrease in blood potassium).</p><p>&bull; Hypersensitivity, swollen face, itchiness, hives, runny nose, nose bleed, cough, snoring.</p><p>&bull; Painful menstrual periods.</p><p>&bull; Coldness of hands and feet.</p><p>Rare: may affect up to 1 in 1,000 people</p><p>&bull; Abnormal sense of smell, swinging vision, altered perception of depth, visual brightness, vision loss.</p><p>&bull; Dilated pupils, cross eyes.</p><p>&bull; Cold sweat, tightness of the throat, swollen tongue.</p><p>&bull; Inflammation of the pancreas.</p><p>&bull; Difficulty in swallowing.</p><p>&bull; Slow or reduced movement of the body.</p><p>&bull; Difficulty with writing properly.</p><p>&bull; Increased fluid in the abdomen.</p><p>&bull; Fluid in the lungs.</p><p>&bull; Convulsions.</p><p>&bull; Changes in the recording of electrical changes (ECG) in the heart which correspond to heart rhythm disturbances.</p><p>&bull; Muscle damage.</p><p>&bull; Breast discharge, abnormal breast growth, breast growth in males.</p><p>&bull; Interrupted menstrual periods.</p><p>&bull; Kidney failure, reduced urine volume, urinary retention.</p><p>&bull; Decrease in white blood cell count.</p><p>&bull; Inappropriate behavior.</p><p>&bull; Allergic reactions (which may include difficulty breathing, inflammation of the eyes (keratitis) and a serious skin reaction characterized by rash, blisters, peeling skin and pain).</p><p>&bull; Jaundice (yellowing of the skin and eyes).</p><p>Very rare: may affect up to 1 in 10,000 people</p><p>&bull; Liver failure.</p><p>&bull; Hepatitis (inflammation of the liver).</p><p>If you experience swollen face or tongue or if your skin turns red and starts to blister or peel, you should seek immediate medical advice.<strong>&nbsp;</strong></p><p>Certain side effects may be more common, such as sleepiness, because patients with spinal cord injury may be taking other medicines to treat, for example, pain or spasticity, that have similar side effects to Pregabalin and the severity of these effects may be increased when taken together.</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep this medicine out of the sight and reach of children.</p><p>- Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.</p><p>- Store below 30&deg;C</p><p>- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is pregabalin. Each hard capsule contains either 75 mg, 150 mg</p><p>The other ingredients are: Microcrystalline Cellulose, Low Substituted Hydroxypropyl cellulose, Stearic acid.</p><p>Lyrgaba Capsules for Oral Use.</p><p>Lyrgaba Capsules are packed in PVC/PVDC/Alu blisters</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pack Size:
40 capsules
60 capsules
500 capsules
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Middle East Pharmaceutical Industries Company (Avalon Pharma) P.O.Box 4180 Riyadh 11491, Kingdom of Saudi Arabia 2nd Industrial City, Riyadh, Kingdom of Saudi Arabia Tel: +966 (11) 2653948 -2653427 Fax: +966 (11) 2654723</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in {10/2024}; version number {06}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي ليرغابا إلى مجموعة من الأدوية التي تستخدم لعلاج الصرع، وآلام الأعصاب، واضطراب القلق العام لدى البالغين.</p><p dir="RTL"><strong>آلام</strong><strong> الأعصاب المحيطية والمركزية</strong><strong>:</strong> يستخدم ليرغابا لعلاج الألم طويل الأمد، الناتج عن الضرر الناشيء في الأعصاب. حيث يمكن أن تسبب مجموعة<strong> </strong>متنوعة من الأمراض ألمًا بالأعصاب المحيطية مثل مرض السكري أو الهربس النطاقي. ويمكن وصف أحاسيس الألم بأنها سخونة، حرق، خفقان، رشق، طعن، حاد، تشنجات، وجع، وخز، خدر، إبر ودبابيس. وقد ترتبط الآم الأعصاب المحيطية والمركزية أيضًا بتغيرات المزاج واضطراب النوم والتعب )الإعياء(، وقد تؤثر على الأداء البدني والاجتماعي والجودة العامة للحياة.</p><p dir="RTL"><strong>الصرع</strong><strong>:</strong> يُستخدم ليرغابا لعلاج شكل معين من أشكال الصرع )النوبات الجزئية مع أو بدون تعميم ثانوي( لدى البالغين. وسوف يصف لك طبيبك عقار<strong> </strong>ليرغابا لمساعدتك في علاج الصرع إذا لم يستطع علاجك الحالي السيطرة على حالتك، وينبعي تناول ليرغابا بالإضافة إلى العلاج الحالي. لم يصمم ليرغابا لاستخدامه بمفرده، ولكن يجب دائمًا استخدامه جنبًا إلى جنب مع العلاجات الأخرى المضادة للصرع.</p><p dir="RTL"><strong>اضطراب</strong><strong> القلق العام</strong><strong>:</strong> يستخدم ليرغابا لعلاج اضطراب القلق العام. وتتضمن أعراض اضطراب القلق العام التوتر والقلق المفرط الممتد الذي يصعب<strong> </strong>السيطرة عليهم. كما يمكن أن يسبب اضطراب القلق العام الشعور بالتململ، أو أنك تحت ضغط شديد، التعب بسرعة، الإعياء، صعوبة في التركيز، أو أن يصبح ذهنك فارغ، سرعة الانفعال، شد في العضلات، أو اضطراب في النوم، كل هذا يختلف باختلاف ضغوط وتوترات الحياة اليومية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول ليرغابا إذا:</p><p dir="RTL">كنت تعاني من حساسية ارتفاع ضغط الدم لبريجابالين، أو لأي مكونات أخرى بهذا الدواء.</p><p>التحذيرات والاحتياطات</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول ليرغابا.</p><p dir="RTL">&bull; أبلغ بعض المرضى الذين يتناولون ليرغابا عن أعراض تشير إلى رد فعل تحسسي. وتشمل هذه الأعراض تورم في الوجه والشفتين واللسان والحلق، وأيضًا طفح جلدي منتشر. إذا واجهت أي من هذه الأعراض، ينبغي عليك الاتصال بطبيبك على الفور.</p><p dir="RTL">&bull; يرتبط ليرغابا بالدوخة والنعاس، مما قد يزيد من حدوث الإصابات العرضية السقوط في حالة المرضى كبار السن. لذلك، ينبغي عليك توخي الحذر حتى تعتاد على أي آثار قد تنتج عن هذا الدواء.</p><p dir="RTL">&bull; قد يسبب ليرغابا التشويش أو فقدان الرؤية، أو تغييرات أخرى في الإبصار، والكثير من هذه الأعراض تكون مؤقتة. ينبغي إبلاغ طبيبك فورًا إذا واجهت أي تغييرات في الرؤية.</p><p dir="RTL">&bull; قد يحتاج بعض المرضى المصابين بداء السكري، والذين ازداد وزنهم في أثناء تناول ليرغابا، إلى تغيير أدوية السكري.</p><p dir="RTL">&bull; قد تكون بعض الأعراض الجانبية أكثر شيوعًا مثل النعاس، بسبب احتمالية تناول المرضى الذين يعانون من إصابة في الحبل الشوكي لأدوية أخرى لعلاج الألم أو التشنج على سبيل المثال، والذي قد تكون لها أعراض جانبية مماثلة لليرغابا، وقد تزداد شدة هذه الأعراض عند تناولها معًا.</p><p dir="RTL">&bull; أبلغ بعض المرضى عن قصور في القلب عند تناول ليرغابا ، كان معظم هؤلاء المرضى من كبار السن الذين يعانون من أمراض القلب والأوعية الدموية. ينبغي عليك إخبار طبيبك قبل تناول هذا الدواء، إذا كان لديك تاريخ من أمراض القلب.</p><p dir="RTL">&bull; تم الإبلاغ عن مشاكل حادة في التنفس. أحياناً، كانت مميته. قد يكون الخطر أكبر عند الأشخاص الذين يتناولون أدوية معينة مثل عقاقير ألم الأفيونيات وغيرها من مثبطات الجهاز العصبي المركزي (CNS) أو أولئك الذين يعانون من مشاكل صحية معينة مثل مرض الانسداد الرئوي المزمن (COPD). قد يكون الخطر أكبر أيضًا لدى الأشخاص الذين تزيد أعمارهم عن 65 عامًا. إذا كانت لديك أسئلة، فتحدث مع الطبيب.</p><p dir="RTL">&bull; أبلغ بعض المرضى عن الإصابة بالفشل الكلوي عند تناول ليرغابا. إذا لاحظت في أثناء تناول ليرغابا انخفاضًا في البول، ينبغي عليك إخبار طبيبك، حيث إن إيقاف الدواء قد يحسّن ذلك.</p><p dir="RTL">&bull; راود عدد قليل من المرضى الذين يتناولون مضادات الصرع مثل ليرغابا بعض الأفكار عن أذية أو قتل أنفسهم. في حال راودتك مثل هذه الأفكار في أي وقت، اتصل بطبيبك على الفور.</p><p dir="RTL">&bull; عند تناول ليرغابا مع أدوية أخرى قد تسبب الإمساك مثل بعض أنواع أدوية الألم، فمن الممكن التعرض لمشكلات بالجهاز الهضمي )مثل الإمساك أو انسداد الأمعاء أو الشلل المعوي.( أخبر طبيبك إذا كنت تعاني من الإمساك، خاصة إذا كنت عرضة لهذه المشكلات.</p><p dir="RTL">&bull; ينبغي عليك قبل تناول هذا الدواء إخبار طبيبك إذا كان لديك تاريخ من إدمان الكحول أو تعاطي مواد الإدمان أو الاعتماد عليها. لا تتناول الدواء أكثر من الجرعة المحددة.</p><p dir="RTL">&bull; تم الإبلاغ عن حدوث تشنجات عند تناول ليرغابا أو بعد التوقف عن استخدامه بفترة وجيزة. في حال تعرضت لتشنجات، اتصل بطبيبك على الفور.</p><p dir="RTL">&bull; أبلغ بعض المرضى ممن يعانون من أمراض أخرى عن انخفاض في وظيفة الدماغ اعتلال الدماغ عند تناول ليرغابا. أخبر طبيبك إذا كان لديك تاريخ من أية حالات طبية خطرة بما في ذلك أمراض الكبد أو الكلى.</p><p>الأطفال والمراهقين:</p><p dir="RTL">لم تثبت سلامة وفعالية الدواء بالنسبة للأطفال والمراهقين دون سن 18؛ ولذلك، لا ينبغي إعطاء ليرغابا لهذه الفئة من المرضى.</p><p>الأدوية الأخرى وليرغابا:</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">قد تتداخل بعض الأدوية الأخرى مع ليرغابا بالتفاعل. عند تناول بعض الأدوية الأخرى، فقد يحفز ليرغابا الآثار الجانبية الموجودة بتلك الأدوية، بما في ذلك فشل الجهاز التنفسي والغيبوبة. وقد تتزايد درجة الدوخة والنعاس وانخفاض التركيز في حالة تناول ليرغابا مع بعض الأدوية التي تحتوي على: أوكسيكودون &ndash; يستخدم كمسكّن للألم.</p><p dir="RTL">لورازيبام &ndash; يستخدم لعلاج القلق. الكحول.</p><p dir="RTL">الأدوية الأفيونية)الأبيود( ومثبطات الجهاز العصبي المركزي</p><p dir="RTL">راقب أعراض ضيق التنفس والتخدير إذا كنت تتناول علاج مصاحب للأفيونيات)الأوبيود( أو مثبطات الجهاز العصبي المركزي مثل البنزوديازيبين. يمكن تناول ليرغابا مع وسائل منع الحمل عن طريق الفم.</p><p>ليرغابا مع الطعام والشراب والكحول</p><p dir="RTL">يمكن أن تؤخذ كبسولات ليرغابا مع أو بدون الطعام. ينصح بعدم شرب الكحول عند أخذ ليرغابا</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">لا ينبغي تناول ليرغابا في أثناء الحمل أو الرضاعة الطبيعية، ما لم يخبرك الطبيب بخلاف ذلك، ينبغي استخدام وسائل حمل فعالة مع النساء المحتمل حملهن. إذا كنتِ حامل أو مرضعة، أو تظنين أنك حامل، أو تخططين لإنجاب طفل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p>القيادة واستخدام الآلآت</p><p dir="RTL">قد يسبب ليرغابا الدوخة والنعاس وانخفاض التركيز، فلا ينبغي عليك القيادة أو تشغيل الآلآت المعقدة أو المشاركة في أي أنشطة ذات مخاطر محتملة؛ وذلك لحين التعرّف على ما إذا كان الدواء يؤثر على قدرتك على أداء هذه الأنشطة.</p><p>ليرغابا يحتوي على اللاكتوز أحادي السكريات:</p><p dir="RTL">إذا كان قد أخبرك طبيبك أنك تعاني من عدم تحمل بعض أنواع السكر، فاتصل بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- تناول دائمًا هذا الدواء كما أخبرك طبيبك تمامًا. وتحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد. - سيحدد طبيبك ما هي الجرعة المناسبة لك.</p><p dir="RTL">- يستخدم ليرغابا عن طريق الفم فقط.</p><p>ألم الأعصاب المحيطية والمركزية، أو الصرع، أو اضطراب القلق العام:</p><p dir="RTL">- تناول عدد الكبسولات التي يوصي بها الطبيب.</p><p dir="RTL">- الجرعة المناسبة لك ولحالتك سوف تتراوح عمومًا ما بين 150 ملجم و 600 ملجم يوميًّا.</p><p dir="RTL">- سوف ينصحك طبيبك بتناول ليرغابا سواء مرتين أو ثلاث مرت يوميًّا. في حالة مرتين يوميًّا، تناول ليرغابا مرة صباحًا ومرة مساءً، في الوقت نفسه تقريبًا في كل يوم. في حالة ثلاث مرات، تناول ليرغابا مرة صباحًا ومرة بعد الظهر ومرة مساءً، في الوقت نفسه تقريبًا في كل يوم.</p><p dir="RTL">- إذا كان لديك انطباع أن تأثير ليرغابا قوي جدًا أو ضعيف جدًا، تحدث مع طبيبك أو الصيدلي.</p><p dir="RTL">- إذا كنت مريضًا مسنًّا أكثر من 65 عامًا، ينبغي عليك تناول ليرغابا بصورة طبيعية، باستثناء ما إذا كنت تعاني من مشكلات في الكليتين. - قد يصف طبيبك جدول جرعات مختلف و/أو جرعات مختلفة إذا كنت تعاني من مشكلات في الكليتين.</p><p dir="RTL">- ابتلع الكبسولة بالكامل بالماء.</p><p dir="RTL">- استمر في تناول ليرغابا حتى يطلب منك طبيبك أن تتوقف عن استخدامه.</p><p>إذا تناولت أكثر مما ينبغي من ليرغابا:</p><p dir="RTL">- اتصل بطبيبك أو توجه إلى أقرب وحدة طوارئ في المستشفى على الفور. خذ كبسولات أو علبة الدواء بالكامل معك, قد تشعر بالنعاس أو التشويش أو الهيجان أو التململ، كنتيجة لتناول جرعة أكثر مما ينبغي من ليرغابا. تم الإبلاغ أيضًا عن نوبات صرع.</p><p>إذا نسيت تناول ليرغابا:</p><p dir="RTL">من المهم تناول كبسولات ليرغابا باستمرار في الوقت نفسه في كل يوم. إذا نسيت تناول جرعة، فتناولها فورًا بمجرد تذكرها، ما لم يكن قد حان موعد جرعتك التالية. في هذه الحالة، استمر في تناول الجرعة التالية كالمعتاد. لا تتناول جرعة مضاعفة لتعويض جرعة منسية.</p><p>إذا توقفت عن استخدام ليرغابا:</p><p dir="RTL">لا تتوقف عن استخدام ليرغابا ما لم يخبرك طبيبك بذلك. إذا تم توقيف علاجك، فيجب أن يتم ذلك تدريجيًا على مدى أسبوع على الأقل.</p><p dir="RTL">بعد التوقف عن تناول الدواء لمدى قصير أو طويل، فإنك سوف تحتاج لمعرفة ما إذا كنت ستعاني من آثار جانبية محددة. وتشمل هذه الآثار صعوبة في النوم، والصداع، والغثيان، والشعور بالقلق، والإسهال، وأعراضًا تشبه الأنفلونزا، وتشنجات، واكتئاب، وألم، وتعرق، ودوخة. قد تحدث هذه الأعراض على نحو أكثر شيوعًا أو أكثر شدة إذا كنت تتناول ليرغابا لفترة زمنية أطول.</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، استشر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، قد يُسبب هذا الدواء أعراضًا جانبية، على الرغم من عدم حدوثها لكل الأشخاص.</p><p>الشائعة جدًّا: قد تؤثر على أكثر من 1 من كل 10 أشخاص</p><p dir="RTL">الدوخة، النعاس، الصداع.</p><p>الشائعة قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص</p><p dir="RTL">&bull; زيادة الشهية.</p><p dir="RTL">&bull; الشعور بالغبطة، الارتباك، التوهان، انخفاض الاهتمام الجنسي، سرعة الانفعال.</p><p dir="RTL">&bull; اضطراب في التركيز، الوهن، ضعف الذاكرة، فقدان الذاكرة، الارتعاش، صعوبة في التحدث، شعور بالوخز، التنميل، التخدير، الخمول، الأرق، التعب، الشعور على نحو غير طبيعي.</p><p dir="RTL">&bull; عدم وضوح الرؤية، ازدواجية الرؤية.</p><p dir="RTL">&bull; الدوار، مشكلات في التوازن، السقوط.</p><p dir="RTL">&bull; جفاف الفم، الإمساك، القيء، الانتفاخ، الإسهال، الغثيان، تورم البطن.</p><p dir="RTL">&bull; صعوبات في الانتصاب.</p><p dir="RTL">&bull; تورم في الجسم بما في ذلك الأطراف.</p><p dir="RTL">&bull; الشعور بالسكر، نمط غير طبيعي في المشي.</p><p dir="RTL">&bull; زيادة الوزن.</p><p dir="RTL">&bull; تشنج العضلات، الآم المفاصل، الآم الظهر، الآم في الأطراف.</p><p dir="RTL">&bull; التهاب الحلق.</p><p>غير الشائعة: قد تؤثر على ما يصل إلى 1 من كل 100 شخص</p><p dir="RTL">&bull; فقدان الشهية، فقدان الوزن، انخفاض سكر الدم، ارتفاع سكر الدم.</p><p dir="RTL">&bull; تغير في إدراك الذات، التململ، الاكتئاب، الانفعال، تقلب المزاج، صعوبة العثور على الكلمات، الهلوسة، الأحلام غير العادية، نوبات هلع، اللامبالاة، العدوانية، المزاج المرتفع، الضعف العقلي، صعوبة في التفكير، زيادة في الاهتمام الجنسي.، مشكلات في الأداء الجنسي تشمل عدم القدرة على الوصول للنشوة الجنسية، تأخر القذف.</p><p dir="RTL">&bull; تغيرات في الإبصار، الحركة غير الاعتيادية للعين، تغييرات في الرؤية تشمل رؤية ضيقة، ومضات من الضوء، حركات متشنجة، انخفاض ردود الافعال الانعكاسية، زيادة النشاط، الدوخة عند الوقوف، حساسية البشرة، فقدان التذوق، الحرقان، الارتعاش عند الحركة، انخفاض الوعي، فقدان الوعي، الإغماء، زيادة الحساسية للضوضاء، الشعور بالإعياء.</p><p dir="RTL">&bull; جفاف العينين، تورم العين، ألم العين، ضعف العينين، العيون الدامعة، تهيج العينين.</p><p dir="RTL">&bull; اضطراب نظم القلب، زيادة معدل ضربات القلب، انخفاض ضغط الدم، ارتفاع ضغط الدم، تغييرات في ضربات القلب، قصور القلب.</p><p dir="RTL">&bull; التورد، الهبّات الحارة.</p><p dir="RTL">&bull; صعوبة في التنفس، جفاف الأنف، احتقان الأنف.</p><p dir="RTL">&bull; زيادة إنتاج اللعاب، حرقة في المعدة، خدر حول الفم.</p><p dir="RTL">&bull; التعرق، الطفح الجلدي، القشعريرة، الحمى.</p><p dir="RTL">&bull; ارتعاش العضلات، تورم المفاصل، تصلب العضلات، ألم بما في ذلك ألم العضلات وألم الرقبة.</p><p dir="RTL">&bull; ألم الثدي.</p><p dir="RTL">&bull; صعوبة في التبول أو ألم، سلس البول.</p><p dir="RTL">&bull; الضعف، العطش، ضيق الصدر.</p><p dir="RTL">&bull; تغييرات في نتائج اختبارات الدم والكبد )زيادة فسفوكيناز الكرياتين في الدم، زيادة ألانين أمينو ترانسفيريز، أسبرتات أمينو ترانسفيراز، انخفاض عدد الصفائح الدموية، قلة العدلات، زيادة الكرياتين في الدم، انخفاض البوتاسيوم في الدم.(</p><p dir="RTL">&bull; فرط الحساسية، تورم الوجه، الحكة، الشري الجلدي، سيلان الأنف، نزيف الأنف، السعال، الشخير.</p><p dir="RTL">&bull; دورات حيض مؤلمة.</p><p dir="RTL">&bull; برودة اليدين والقدمين.</p><p>نادرة: قد تؤثر على ما يصل إلى 1 من كل 1000 شخص</p><p dir="RTL">&bull; الإحساس غير الطبيعي بالرائحة، الرؤية المتأرجحة، تغير تصور العمق، سطوع الرؤية، فقدان الرؤية.</p><p dir="RTL">&bull; توسع الحدقة، حول العينين.</p><p dir="RTL">&bull; عرق بارد، ضيق الحلق، تورم اللسان.</p><p dir="RTL">&bull; التهاب البنكرياس.</p><p dir="RTL">&bull; صعوبة في البلع.</p><p dir="RTL">&bull; بطأ أو انخفاض حركة الجسم.</p><p dir="RTL">&bull; صعوبة الكتابة بشكل صحيح.</p><p dir="RTL">&bull; زيادة السوائل في البطن.</p><p dir="RTL">&bull; سوائل في الرئة.</p><p dir="RTL">&bull; التشنجات.</p><p dir="RTL">&bull; تغييرات في تسجيل التغييرات الكهربائية في القلب التي تتوافق مع اضطرابات نظم القلب.</p><p dir="RTL">&bull; تلف العضلات.</p><p dir="RTL">&bull; إفراز سوائل من الثدي، نمو الثدي غير الطبيعي، نمو الثدي لدى الذكور.</p><p dir="RTL">&bull; توقف دورات الحيض.</p><p dir="RTL">&bull; الفشل الكلوي، انخفاض كمية البول، احتباس البول.</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم البيضاء.</p><p dir="RTL">&bull; السلوك غير اللائق.</p><p dir="RTL">&bull; ردود الفعل التحسسية، والتي قد تشمل صعوبة في التنفس، التهاب في العينين )التهاب القرنية(، ورد فعل جلدي حاد يتميز بالطفح الجلدي، بثور، تقشر الجلد والألم.</p><p dir="RTL">&bull; )اليرقان( اصفرار الجلد والعينين.</p><p>نادرة جدًّا: قد تؤثر على ما يصل إلى 1 من كل 10000 شخص</p><p dir="RTL">&bull; تليف الكبد.</p><p dir="RTL">&bull; التهاب الكبد الفيروسي (التهاب الكبد).</p><p>إذا ظهر لديك تورم في الوجه أو اللسان. أو احمرار في الجلد، وبدأ في إخراج البثور أو التقشير، فينبغي عليك استشارة الطبيب على الفور:</p><p dir="RTL">قد تكون بعض الأعراض الجانبية أكثر شيوعًا مثل النعاس، بسبب احتمالية تناول المرضى الذين يعانون من إصابة في الحبل الشوكي لأدوية أخرى لعلاج الألم أو التشنج على سبيل المثال، والذي قد تكون لها أعراض جانبية مماثلة لليرغابا، وقد تزداد شدة هذه الأعراض عند تناولها معًا. إذا كنت تعاني من أي أعراض جانبية، فتحدث مع طبيبك أو الصيدلي. ويشمل ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">-يتم تخزينه في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">-لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدوَّن على الملصق والعلبة. تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من الشهر.</p><p dir="RTL">-ينبغي عدم التخلُّص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي الخاص بك عن كيفية التخلُّص من الأدوية التي لم تعد لازمة. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- المادة الفعالة هي بريجابالين. وتحتوي كل كبسولة صلبة على إما 75 ملجم أو 150 ملجم.</p><p>- المكونات األخرى هي: ميكروكريستالين سيليلوز، هيدروكسي بروبيل السليلوز منخفض التركيز، حمض الستريك. - كبسوالت ليرغابا لالستعمال عن طريق الفم فقط.</p><p>- كبسوالت ليرغابا مغلفة في شريط شفاف/ رقائق ألومنيوم PVDC/PVC.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الحجم:</p><ul><li>40 كبسولة</li><li>60 كبسولة</li><li>500 كبسولة</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة الشرق الأوسط للصناعات الدوائية )أفالون فارما( ص.ب. 4180 الرياض 11491، المملكة العربية السعودية المدينة الصناعية الثانية، الرياض</p><p dir="RTL">هاتف: 2653427 - 2653448 (11) 00966</p><p dir="RTL">فاكس: 2654723 (11) 00966</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النشرة بتاريخ [2024/10]، رقم النسخة {06}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lyrgaba 75 mg hard capsules
Lyrgaba 150 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lyrgaba 75 mg hard capsules:
Each hard capsule contains 75 mg of pregabalin.
Lyrgaba 150 mg hard capsules
Each hard capsule contains 150 mg of pregabalin.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsules.
Lyrgaba 75 mg hard capsules
White body and white cap hard gelatin capsule size (3), filled with off-white powder.
 Lyrgaba 150 mg hard capsules
White body and white cap hard gelatin capsule size (2), filled with off-white powder.
 For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Neuropathic pain</u></p><p>Lyrgaba is indicated for the treatment of peripheral and central neuropathic pain in adults. <u>Epilepsy</u></p><p>Lyrgaba is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. <u>Generalised anxiety disorder</u></p><p>Lyrgaba is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The dose range is 150 to 600 mg per day given in either two or three divided doses.</p><p><u>Neuropathic pain</u></p><p>Pregabalin treatment can be started at a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.</p><p><u>Epilepsy</u></p><p>Pregabalin treatment can be started with a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. The maximum dose of 600 mg per day may be achieved after an additional week.</p><p><u>Generalised anxiety disorder</u></p><p>The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly.</p><p>Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. Following an additional week, the dose may be increased to 450 mg per day. The maximum dose of 600 mg per day may be achieved after an additional week.</p><p><u>Discontinuation of pregabalin</u></p><p>In accordance with current clinical practice, if pregabalin has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week independent of the indication (see sections 4.4 and 4.8).</p><p><u>Renal impairment</u></p><p>Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. As pregabalin clearance is directly proportional to creatinine clearance (see section 5.2), dose reduction in patients with compromised renal function must be individualised according to creatinine clearance (CLcr), as indicated in Table 1 determined using the following formula:</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Image_x0020_9" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:375pt;height:49.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/NAWAF~1.ALB/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="500" height="66" src="data:image/jpeg;base64,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" /></p><p>&nbsp;</p><p>Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4-hour haemodialysis treatment (see Table 1).</p><p>Table 1. Pregabalin Dose Adjustment Based on Renal Function</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance (CL</strong><strong>cr</strong><strong>)</strong></p><p><strong>(ml/min)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Total pregabalin daily dose*</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Dose regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Starting dose (mg/day)</p></td><td style="vertical-align:top"><p>Maximum dose (mg/day)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 60</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>BID or TID</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 30 - &lt; 60</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>BID or TID</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&ge; 15 - &lt; 30</p></td><td style="vertical-align:top"><p>25 &ndash; 50</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>Once Daily or BID</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 15</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>Once Daily</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Supplementary dosage following haemodialysis (mg)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>Single dose+</p></td></tr></tbody></table><p>TID = Three divided doses BID = Two divided doses</p><p>* Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose</p><p>+ Supplementary dose is a single additional dose <u>Hepatic impairment</u></p><p>No dose adjustment is required for patients with hepatic impairment (see section 5.2). <u>Paediatric population</u></p><p>The safety and efficacy of Lyrgaba in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p><u>Elderly</u></p><p>Elderly patients may require a dose reduction of pregabalin due to a decreased renal function (see section 5.2).</p><p><u>Method of administration</u></p><p>Lyrgaba may be taken with or without food.</p><p>Lyrgaba is for oral use only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Diabetic patients</u></p><p>In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycaemic medicinal products.</p><p><u>Hypersensitivity reactions</u></p><p>There have been reports in the postmarketing experience of hypersensitivity reactions, including cases of angioedema. Pregabalin should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper airway swelling occur.</p><p><u>Dizziness, somnolence, loss of consciousness, confusion and mental impairment</u></p><p>Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population. There have also been postmarketing reports of loss of consciousness, confusion and mental impairment. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicinal product.</p><p><u>Vision-related effects</u></p><p>In controlled trials, a higher proportion of patients treated with pregabalin reported blurred vision than did patients treated with placebo which resolved in a majority of cases with continued dosing. In the clinical studies where ophthalmologic testing was conducted, the incidence of visual acuity reduction and visual field changes was greater in pregabalin-treated patients than in placebo-treated patients; the incidence of fundoscopic changes was greater in placebo-treated patients (see section 5.1).</p><p>In the postmarketing experience, visual adverse reactions have also been reported, including loss of vision, visual blurring or other changes of visual acuity, many of which were transient. Discontinuation of pregabalin may result in resolution or improvement of these visual symptoms.</p><p><u>Respiratory Depression</u></p><p>Pregabalin has been associated with serious, life-threatening, and fatal respiratory depression. The risk may be increased with the concomitant use of opioids and other central nervous system (CNS) depressants, and with conditions such as chronic obstructive pulmonary disease. The elderly is also at higher risk. Health care providers should start pregabalin at the lowest dose and monitor patients for symptoms of respiratory depression and sedation when co-prescribing pregabalin with an opioid or other CNS depressants (e.g. benzodiazepines). Patients with underlying respiratory disease and elderly patients are also at increased risk and should be managed similarly.</p><p><u>Renal failure</u></p><p>Cases of renal failure have been reported and in some cases discontinuation of pregabalin did show reversibility of this adverse reaction.</p><p><u>Withdrawal of concomitant anti-epileptic medicinal products</u></p><p>There are insufficient data for the withdrawal of concomitant anti-epileptic medicinal products, once seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy on pregabalin.</p><p><u>Withdrawal symptoms</u></p><p>After discontinuation of short-term and long-term treatment with pregabalin, withdrawal symptoms have been observed in some patients. The following events have been mentioned: insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, nervousness, depression, pain, convulsion, hyperhidrosis and dizziness, suggestive of physical dependence. The patient should be informed about this at the start of the treatment.</p><p>Convulsions, including status epilepticus and grand mal convulsions, may occur during pregabalin use or shortly after discontinuing pregabalin.</p><p>Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.</p><p><u>Congestive heart failure</u></p><p>There have been postmarketing reports of congestive heart failure in some patients receiving pregabalin. These reactions are mostly seen in elderly cardiovascular compromised patients during pregabalin treatment for a neuropathic indication. Pregabalin should be used with caution in these patients. Discontinuation of pregabalin may resolve the reaction.</p><p><u>Treatment of central neuropathic pain due to spinal cord injury</u></p><p>In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased. This may be attributed to an additive effect due to concomitant medicinal products (e.g. anti-spasticity agents) needed for this condition. This should be considered when prescribing pregabalin in this condition.</p><p><u>Suicidal ideation and behaviour</u></p><p>Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised placebo-controlled studies of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known, and the available data do not exclude the possibility of an increased risk for pregabalin.</p><p>Therefore, patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p><p><u>Reduced lower gastrointestinal tract function</u></p><p>There are postmarketing reports of events related to reduced lower gastrointestinal tract function (e.g. intestinal obstruction, paralytic ileus, constipation) when pregabalin was co-administered with medications that have the potential to produce constipation, such as opioid analgesics. When pregabalin and opioids will be used in combination, measures to prevent constipation may be considered (especially in female patients and elderly).</p><p><u>Misuse, abuse potential or dependence</u></p><p>Cases of misuse, abuse and dependence have been reported. Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of pregabalin misuse, abuse or dependence (development of tolerance, dose escalation, drug-seeking behaviour have been reported).</p><p><u>Encephalopathy</u></p><p>Cases of encephalopathy have been reported, mostly in patients with underlying conditions that may precipitate encephalopathy.</p><p><u>Lactose intolerance</u></p><p>Lyrgaba contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (&lt; 2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions.</p><p><u>In vivo studies and population pharmacokinetic analysis</u></p><p>Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance.</p><p><u>Oral contraceptives, norethisterone and/or ethinyl oestradiol</u></p><p>Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance.</p><p><u>Central nervous system influencing medical products</u></p><p>Pregabalin may potentiate the effects of ethanol and lorazepam. In controlled clinical trials, multiple oral doses of pregabalin co-administered with oxycodone, lorazepam, or ethanol did not result in clinically important effects on respiration. In the postmarketing experience, there are reports of respiratory failure and coma in patients</p><p>taking pregabalin and other central nervous system (CNS) depressant medicinal products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.</p><p><u>Opioids and CNS depressants</u></p><p>Serious respiratory depression may occur with pregabalin when co-administered with opioids and CNS depressants such as benzodiazepine. Therefore, monitor for symptoms of respiratory depression and sedation in patients who require concomitant treatment with opioids or CNS depressants</p><p><u>Interactions and the elderly</u></p><p>No specific pharmacodynamic interaction studies were conducted in elderly volunteers. Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p>As the potential risk for humans is unknown, effective contraception must be used in women of childbearing potential.</p><p><u>Pregnancy</u></p><p>There are no adequate data from the use of pregabalin in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>Lyrgaba should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus).</p><p><u>Breast-feeding</u></p><p>Pregabalin is excreted into human milk (see section 5.2). The effect of pregabalin on new-borns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue pregabalin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>There are no clinical data on the effects of pregabalin on female fertility.</p><p>In a clinical trial to assess the effect of pregabalin on sperm motility, healthy male subjects were exposed to pregabalin at a dose of 600 mg/day. After 3 months of treatment, there were no effects on sperm motility.</p><p>A fertility study in female rats has shown adverse reproductive effects. Fertility studies in male rats have shown adverse reproductive and developmental effects. The clinical relevance of these findings is unknown (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lyrgaba may have minor or moderate influence on the ability to drive and use machines. Lyrgaba may cause dizziness and somnolence and therefore may influence the ability to drive or use machines. Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pregabalin clinical programme involved over 8,900 patients exposed to pregabalin, of whom over 5,600 were in double-blind placebo-controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity. In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving pregabalin and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.</p><p>In table 2 below all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency (very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>The adverse reactions listed may also be associated with the underlying disease and/or concomitant medicinal products.</p><p>In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, CNS adverse reactions and especially somnolence was increased (see section 4.4).</p><p>Additional reactions reported from postmarketing experience are included in italics in the list below.</p><p>Table 2. Pregabalin Adverse Drug Reactions</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse drug reactions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nasopharyngitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neutropaenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p><em>Hypersensitivity</em></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>Angioedema, allergic reaction</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Appetite increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anorexia, hypoglycaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Euphoric mood, confusion, irritability, disorientation, insomnia, libido decreased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hallucination, panic attack, restlessness, agitation, depression, depressed mood, elevated mood, <em>aggression, </em>mood swings, depersonalisation, word finding difficulty, abnormal dreams, libido increased, anorgasmia, apathy</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Disinhibition</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Dizziness, somnolence, headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Ataxia, coordination abnormal, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Syncope, stupor, myoclonus, <em>loss of consciousness, </em>psychomotor hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, cognitive</p><p>disorder, <em>mental impairment, </em>speech disorder, hyporeflexia, hyperaesthesia, burning sensation, ageusia, <em>malaise</em></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>Convulsions, </em>parosmia, hypokinesia, dysgraphia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vision blurred, diplopia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Peripheral vision loss, visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, photopsia, dry eye, lacrimation increased, eye irritation</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>Vision loss, keratitis, </em>oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hyperacusis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tachycardia, atrioventricular block first degree, sinus bradycardia, <em>congestive heart failure</em></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>QT prolongation, </em>sinus tachycardia, sinus arrhythmia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypotension, hypertension, hot flushes, flushing, peripheral coldness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dyspnoea, epistaxis, cough, nasal congestion, rhinitis, snoring, nasal dryness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>Pulmonary oedema, </em>throat tightness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting, <em>nausea, </em>constipation, <em>diarrhoea, </em>flatulence, abdominal distension, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastrooesophageal reflux disease, salivary hypersecretion, hypoaesthesia oral</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Ascites, pancreatitis, <em>swollen tongue, </em>dysphagia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Elevated liver enzymes*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hepatic failure, hepatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash papular, urticaria, hyperhidrosis, <em>pruritus</em></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>Stevens Johnson syndrome, </em>cold sweat</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Muscle cramp, arthralgia, back pain, pain in limb, cervical spasm</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rhabdomyolysis</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urinary incontinence, dysuria</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Renal failure, oliguria, <em>urinary retention</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Sexual dysfunction, ejaculation delayed, dysmenorrhoea, breast pain</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Amenorrhoea, breast discharge, breast enlargement, <em>gynaecomastia</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Oedema peripheral, oedema, gait abnormal, fall, feeling drunk, feeling abnormal, fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Generalised oedema, <em>face oedema, </em>chest tightness, pain, pyrexia, thirst, chills, asthenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Blood creatine phosphokinase increased, blood glucose increased, platelet count decreased, blood creatinine increased, blood potassium decreased, weight decreased</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>White blood cell count decreased</p></td></tr></tbody></table><p>* Alanine aminotransferase increased (ALT) and aspartate aminotransferase increased (AST).</p><p>After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms have been observed in some patients. The following reactions have been mentioned: insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, convulsions, nervousness, depression, pain<strong>, </strong>hyperhidrosis and dizziness, suggestive of physical dependence. The patient should be informed about this at the start of the treatment.</p><p>Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose related.</p><p><u>Paediatric population</u></p><p>The pregabalin safety profile observed in four paediatric studies in patients with partial seizures with or without secondary generalisation (12-week efficacy and safety study in patients 4 to 16 years of age, n=295; 14-day efficacy and safety study in patients 1 month to younger than 4 years of age, n=175; pharmacokinetic and tolerability study, n=65; and 1 year open label follow on safety study, n=54) was similar to that observed in the adult studies of patients with epilepsy. The most common adverse events observed in the 12-week study with pregabalin treatment were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis. The most common adverse events observed in the 14-day study with pregabalin treatment were somnolence, upper respiratory tract infection, and pyrexia (see sections 4.2, 5.1 and 5.2).</p><p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAmEAAAEnCAYAAADhHJSnAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAADPiSURBVHhe7d0/bhrP48bxZ3OMKIosljOkiHCKFF4OkAJcuYq01BE0Kd0s+tRGcuUqbOEDgAsXBqXIGVhkWVaOkfkVX2Z+s8OCsWNnnfj9klDM7L/Z2TU8mRlMZIwxAgAAwB/1KiwAAADA0yOEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADU4ElCWJ7niqJo62M+n4ebbbVcLtf24T+wu3a7rXa7HRY7vV5PzWYzLH40vV7PXbfhcChJGg6HrqzX64WbAADwz3mSEHZzc6Msy2SMkTFGcRwrTVP3PE1T3d7ehptt1Wg03LZxHLt9FUUhSQSxe5hMJppMJmGxtApIo9EoLH40NnQZY5RlmQaDgfI81+XlpYwxGo/HGo1GWi6X4aYAAPxTniSESVK/3w+LnC9fvoRFD9ZoNJRlmSTdu3ftseV5rjzPw+K/ysnJidI0DYsfzenpqT58+CCt7hFjjM7OzvTx40dJUqfTkTFGjUYj2HI323r4AAB4Tp4khG0LYFoFp06nExb/9brdbliEgO259C0Wi7DoQYbD4aPtCwCAp/YkIey+/Lld950PlOe5BoOB0jRVq9UqLfPnGflznObzuaIoKs0zC+dA2XXsw+/hssv8/dvh0G63u3FoNNyn32tj59HJaw+73J9DZcv8ulcN3fnHms/npfo3m821dm6324oq2sFqNptuf3ZIcZOqdf3zs21k268oCg0GA0VeO2+6duEyu89er6fBYKCiKErHtXXJ87x0zrYcAIDamD8gjmOTpmlYbIwxRpKZzWbGGGOKojCSNq5rjDFpmhpJpUeVLMtMlmXueZIkJkkSM5vN1rYNj2vXscbjsZFkxuNxafuwnnadTeI4dnWy+5nNZm7/fp385cargy9NU1MURanMiuPY/ezXK47jtbonSeKe27bwt4/j2B3HLt90nnetGz43QbuYLdfOLgvrZuseLsuyzB0rTVO3DwAAnoPqBPPINoWwLMvW3hht2NgULtI0dW+0WZZtXNeGjfBhvIDjb2f3ZVZv+n4IMMFxq7Y3GwJGFT90bQpZNsDY5aYirFS1qbWpzU2wLAycZsO5ho+qfe+yblUbhee17dopaBNfVQiz2wEA8NzUOhx5fX0dFunNmzeSpJ8/f4aL1vT7fSVJooODg3CRiqJQURSyn6K0j03evn3rfq6aV7S3t1c5n+k+7JDc1dXVg/Z1fHyswWAgrfZ1eHgYruIcHx9rNBqVhuyq3PUp1dvbWyVJstaOJycn4ar3WnebTdeuath1Gzs30bbB3/6hCQDAv6XWECZJ0+k0LJIkvX79OiyqNJlMVBTF2hynOI7148ePUtk2Nzc3iuPYPb+8vCwt12qfD7VcLtXtdjWbze4dSqxOp6M4jjUcDnV1dbU2B85nP2U4m82k1RyobTYFnDdv3my8RqH7rLvNpmtnPzF5V3D02QAXx7G63W7tn6AFAMCqNYTZP1XhT1D/9u2b0jS9158omM1mGo1Gpf18/vxZ3W63FC7CoHZ+fu5+HgwGOj4+lla9SNPptDQB/fT01C2/S57nG0ONDRBVIWMXtjdsb28vXFRiQ1er1XJBrIr9lKrfNqPRSEVRqNlsqtVqKY7jtT/9ELalVsfadd1ttl27NE03LvMNh0MNh0PX+7VYLH4rRAMA8OjC8cnHFE44V8U8Kjv3yT6q5hqZivUUzC1KvQn7dh9+mb++nbvkLw/ngIV1t9uG5f78pCRJSscPhXW0P4dzoMJjVM2huoudD2Uftt39Y9l6hm3rzwmz/OW647apWjc8J63aLiyz9dx07aqW2Wvg768oCpNl2cZrbNsBAIC6ROZ/b5ovynw+1/7+voqiuFeP23PR6/UePKQJAACeh1qHI3F/w+Fw64R8AADwd3iSnrBtn8YDnpsn+BUAAOBOTxLCAAAAsB3DkQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1ODJQ9hwOFQURYqiSM1mU5KU57nm83m46qPI89wdr91uS5J6vZ6iKFKe5+HqW9n6/q7lcunqFEVRuFhaHSuKIi2Xy3ARAAD4Bz1pCBsOhxoMBkqSRMYYXVxcKIoiff36Va1WK1z9UXQ6HaVpKkk6OjoqLbu5uSk936bX66koirD4QRqNhmazmSS5um3y8+fPsAgAAPyDImOMCQsfS7PZVFEUGo/H6nQ60qqn6urqSicnJ+Hqj8YetygKNRqNcPGdbHiUpMdqnl6vp9FopNls9mQBFAAA/D2etCfMurq6cj+/e/dOHz58KC1/TMvlUkVRKEmSBwWw+XzuAthjuri4kCQCGAAAkJ46hH3+/FmSNBqN3HysRqPhesUUzJeyc7eGw6EUzCezZXbOV6/Xq9xHHMeSpI8fP+40Fyt0dHSk8XgsSW5fCuaa9Xo9V1drPp+vnYc9ZxsM0zQtrRPu185h22V/dhlzyAAA+EuZJ5YkiZFkJJksy0rLZrOZkWSSJDHmf+N+RpIpisKtE8dxqSxNUyPJzGaz0j7SNK1cP1y+TRzHxhhjxuOxkeSeW1mWufPw62rXT9PUFEXhloXb2f2FdbTLx+OxMd7xN+3PL7PtAAAA/i5PHsJMEMRs0DBeGLH8oGK8sGFDWtU6YUCJ47i0PAxtm6Rp6tbZFMKSJDFxHLt17XJ/3ao62/O3whC2rR2q9gcAAP5+TzIcmed5aZhsMpm4ob2zszO3jh2i02r4Td4QpiSdn59Lq6FFrSa3S9LBwYG0Gq6UpCzLpNU+iqIo7WM0GimO461zsYbDoUajkfb39xVFkbrdbriKJGk6nUqSvnz5olarpcVi4epgj/njxw/J+2TmcrnUdDp152mHJuM4VqPRcHW2y+/aHwAA+Dc8SQi7urpyAcryg5G8yfqHh4eSpOPjY0nS+/fv3Tqnp6eSpE+fPmk+n2s0GkmSm9jvL1fFPuwcKhvaqsznc11fX2vVKyhjjJsT5vP35U/4v7y8lLw6fP36VVp9AEFeiLJ1tu1i2+Pbt2+l5XftDwAA/BueJIRdXFxoMBiU/iCrDUx+D5E1HA41nU4Vx7Fub2/dH3O1PUbyApYkvXnzxvUYWb1eb20fttft8PCwNOndms/nOjo6WvtzGVV/T8zu68uXL6XyxWLhfrZ/WyxJEp2fn2s+n7vtOp2O8jx3fzet3+9Lq546rUJWr9e7c392kr7/wQQAAPAXCscnf1dRFG4Cvj8XTMF8MDvvSqsJ6P7PxptQb+dH+ZPR7fwof4K8/3M4SV/BZH/jzSVTMF/M38Yeyx47nCNmgjr452HbINyf/+EE/5zsvu/any1jjhgAAH+3J/1jrQAAAKj2JMORAAAA2I4QBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUIDLGmLDwd0VRpCiKwmIAeBF+/foVFgHAmicJYa9eveJFCMCLxOsfgF0xHAkAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANXixIWw+n7/4PyjbbDaV53lYfKd2u63hcBgWQ9JwOFS73Q6LcYflcvnHfh/zPOcaAXgW/tkQZkNW1aPZbIar/xa73+VyuVY+n89LZVV6vZ56vZ57buu+y7ZPwb4h+o+XGLqazWbpumyy63p1GA6Hj34dnyJo/vfff8qyTPLu//D3NPyPU3iPhtcgvI/t/jqdjqbT6drvKwD8af9sCGu1WjLGyBij8XisOI7d88ViEa7+2+I4XnsTeChb91arFS76o4qikDFGRVFoMBg8qNfsb7ZYLHRychIWr9l1vT+t1+tpMBi4+94Yo8vLy9rC/Taj0Ujv378Pi+8MjbPZzJ3baDRy68/nc8VxrPF47JYfHx+739E0TXV+fh7sDQD+rH82hO0qz/ON/5NuNptu2V3/8z8+PtZ0Ot36BlfVI9FutzUajTQajVwd7P/g/f+p+3WJvN6A+XyuZrNZ6vEIz6PquPfRaDSUpqmurq5K5X6d/LqGvS+WHQbq9XquLmFZFEXK87zUk3mf8/GX+aGx3W6Xltn6RkGPo9/24bCrv7192H2H9bB2bYuo4lz89vWX7XJfzudzjUYjFUVRKp9MJi7c+8f267btnrLBbjqdlo4frdo78nqcwp6o8Pws2/7hfzqOj481GAxKZdtkWabLy0tJ0tHRkbIsU6fTccs7nY4Lyx8+fNDp6albBgB1ePEh7OrqyvX2jEYj94bQbrd1cHDg/hetO/5X/ubNG6VpqqOjo3CRtHrjtD1Ls9lMg8FAy+VSk8lEaZoqTVMZYyp7VJrNZqkuaZqWhmqKotD19XXleWw67u8aDAa6uLhw9bFv0nmeu7oYY5QkSSlETadT7e3tyRijfr+/VjYej9XtdnV0dHTv82k2m8qyzB3769ev0upaSnLlWZYpjmNJUpIk+vbt26p20vn5uZIkUaPRcGVa7cNeo9lsJq3afZv7tEV4LuH9ZwNDWK4N9+X3798Vx/HaeVjD4dBdP9smfqDbdE+dnJwoyzIlSSJjjCaTidvm69evMl5Pc9gTNRgMKv+T8v37dyVJEhar0+k8qId5uVyqKIrKnjXrzZs3d14/AHhy5glEURQW1Wo8Hps4jktls9nMhKefJIkZj8emKAojyRRF4ZZV7cOSZGazmft5PB6vlYf8ZWmamjRN3TL/+FX1vGu5PY8q/nHjOK5cLzx/ewy7XZIkJssyt/5sNtvYNlmWmSRJjNnQhmFZeGyz4/lUtYPZsD/jbTcej0vb+W3in2fYVpvawz/f0F1tEcexmc1mG+tcVV61H3NHPUzF+dznnqrat98eZkO9wvvcL/f35x/f/lxVL/+Ytv6bfn9Du6zzUM/t9Q/A8/Xie8JCNzc37uc4jt1QSrfbLa23ie3JCfnDa/7Qzy5sr41lezd+/vxZKvfZ8/jd40ZRpP39fc1ms7XhIp/fq+AP/d1nOGmbXc4nbCdf2CMUx7Fub2/dcNV8Ptd8PldRFKUhLKvZbLrhWNub8/r162Ctdfdti9vbW/dzWGfrIfdllW636/azre0s/3djF0VRlK7VaDQKV3E2nWur1Sr1tIb29/dd/cfjceW122bb7xAAPDVC2BZ22Ms+dpnQb4dQ/CGi5XLpgozd132EwyZ2yOquEPAYx7XbbQtgPvtmabezn3h7DHedT9hOvnAItigKvXnzRlpN0v727Zu+f/+uNE1L6/nsvL39/X2Nx+ONwcH63bYI62ztcl++f//+zk8A+kOF9nHXOd2H/2EY+6gabteWc5WkL1++aDqd6vv37+Gi0r1gA1ij0VAcxztNvL/rdwgAnhIhrEKj0VCSJPrvv//CRTs5Ozur7PWwL/jhpwz39vY2vgm1Wq21eTH//fdf5bylTTYd96n49XqKyc9V52NDYjiB3V5Lv/2Gw6HiOHbbHB4eajQa6fT0VIeHh24933Q6LYWfXXtcHtIWNkT4959/Lrvcl61WS0mS6ODgoFTe6/U0n8/1+fNnN2fuvt6+fVsZ/HydTkdFUex0z+3t7YVFJY1GQ1mWVf5ObWIn9ftz0ObzubsPbA/Yrr9DAPAUCGEbTCYTXVxclIZTNg2JhOwQilaBwb6J2GGks7Oz0vDPp0+f3KfNqiZZLxYL1wsTrT6550+I3uSu4z6Fk5OTUl3DEPA77jqfYvWnNOyxz87OpNW1XCwWrvz09LQUImzQtT9XsX/mxL8fqiaZ+36nLcJrfnx8LN3zvpxMJjo4OCitu7e3p1arpX6/v7bM/7DHNjZgbTu2VtfDH/KMgk+sWrbXbpt+v684jne+fzudjmazmRuujKJIR0dHrifu9vZ2530BwFOJjLnnGNUOXr16pV+/foXFwF9puVwqjmMVReF6TvI819evX+/sEcJuoii6c97hY7LhcdPw6O/g9Q/ArugJA+5QNXR1c3Ozc88R7pamaeWcr6cyGo02Dj0DwJ9CTxiwg+FwWJqTFMcxvWCPaD6fa39/X0/wcrQmz3OdnZ3tNKT/ELz+AdgVIQwAHhGvfwB2xXAkAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBD2DxsOh2q325Kk5XKpKIq0XC7D1QAAQA0IYTvo9XqKokhRFKnZbLryPM9duX30er21bexjOBx6e/1/w+FQURQpz/Nw0V+r3W5vPN/HYtvftrllA6d92CBqNZvN0nKfvRb24V+T+XxeWhYeFwCA+yCE3WE4HOri4kLGGBljdHx8XHpjjuPYLTPG6OTkxC1L07S0bDAYrAUCSTo9PVWapjo7OwsXYYNms6mrqyulaRouUhzHyrLMtftisXCBsN1uq9lsumVpmrprkue5BoOBiqKQMUaz2UzdblfL5VLL5VL7+/saj8du29Fo9E8FZwDAn/ViQ9iuvRrX19el3q9Op6NOp1NaZ1fGGE2n07XeFUn68uWLptPp1uFCvwfH72Vqt9sbe312EfboWWGPUnjMcDtb92azqel0qsFgUNoubHO/HZrNZml/8nqlqiwWi1LgtWx79vt9V3Z8fKzT01NJ0nQ61devX90yv91tqGs0GpKkVqulJEl0fn6uHz9+KI7j0rXPsozgDAB4sBcZwubzufb39zWbzUq9GlXDZ4eHh5pOpw8KN1WSJNHV1ZV7/u3bNx0cHKjRaLg3/CrtdlsHBweuvjZU9Ho9HR0dufIw5N1lPp+r2+263p/xeOzaIY7jUs/PYDBwIUdSabs0TV2QXSwWSpLE9Ub1+33Xk2TbvCgK18vk788e66Fev34trYKl9ebNGxVFIa3O6du3b26ZDVw/f/7U3t6eRqORW2aXX19fu3345//27VstFovS+gAA7OpFhrBv374pTVO1Wi1XlmWZLi8vS+tp1Rtiw01U0dNUFMXG3qIq9k3fGo1GOjw8lCQdHR25cOVbLpeaTqf68uWLK7Nv/icnJ6XemSRJdHNz457fxbaFrVen01G/31ee52s9P2malgJMlmVuu8PDw62B5Pz8XEmSuDavCp3j8djb4n+9WfcNZI1GQ+PxWN1u112T/f19t/zi4kKj0ah0zax+v68kSUrLbChrtVrKskz7+/tuWbfbddsCAHBfLzKESdLe3l7p+V29GraHZrFYlIJYOCfMHwar4vf82KBjg8m7d+9UFMXGnqwwwFl+aJhOp+HiO4VtYYUBM+wlCtnepk1skP2duu6i0+mUrsl4PFYcx9KqDf1lts62B20ymZSWJ0ni2seGQvvIsqw0VA0AwH282BB2fX1den5zc7PTG+rx8fHWsHaX6XSqDx8+SJLOzs5KQccGhU3zjKrmizWbzdIk9CRJwlXuFLaFFQZME3zw4L6SJFnb312h9TGcnZ3p4OAgLJZWPXRxHFcGXNsD+f79+3CRtPpAxcePH8NiAAB28iJD2OHhoUajUWl+z2Aw0NHRUWk9rUKOH37Ozs52CmtVms2mkiRRp9Nxb/D+vDSz6rUJJ+g3Gg3Fcaz//vuvtC/r7du3khca7uPDhw8ajUbueHmeazgcqtPpbO2Vu4udS2V9+vRJ0+m01OZ32TYxf1fD4XBtKNeaz+caDAY6Pj4OF0mSDg4OSkOovl6vp6Io/kiIBAD8o8wTiKIoLHp2xuOxkeQe4/E4XMUYY8xsNiutlySJWzYej00cx6X1rTRNS9tJMlmWueVZlpX25QvX9cvD+ob1S9PUbesfoygKI8kURVHap13Pbu+fj92m6rhJkpTqaOsRPt9WV0lmNpsZY4yJ43jtGth6VYnjeG1faZoaE7STgnNOkqS0zD9meE/416eqLYAqf8PrH4DnITL/e9N6VK9evdKvX7/CYgD45/H6B2BXL3I4EgAAoG6EMAAAgBoQwgAAAGpACAMAAKgBIQwAAKAGhDAAAIAaEMIAAABqQAj7CyyXS0VRVPm1Rc9Br9dTr9cLi5+dXq/nviKqqi3b7fadX8AOAMBjIYTdwQag8FH1Jv6YHuMre/41tk38x65fIbVcLjUajVQUhYwxld8VCQDAn0QI25F987aPp34T7/f7eoIvM/gr2SB8eXm59gXgnz9/3ikU//z5U1p9pyUAAM/Biw1h8/m81KPyWMNpzWZTeZ6v9dS02+3KXrSwd8fK83xjL0+73Va73Q6LpdUy//j+8ebz+Vr9wv349dzUJn7bhXXM81ztdtsN/Q2Hw7XhynB4NaxveOyDgwONx2NNJhNXZvX7fWVZVvpyc/8cbHvs7+9LUumct7WDVteyqj4hf5jTPuwXn4fnZoc7h8Ph2jHDdrLCfWxqt7uCKADgmQm/TPIxPPcvsLVfJG2/PNps+dLsbV98XcV+sXT43H5RdJqm7ouhx+Ox+9Jps/pyafvc/3LwsA5Jkmz88m/7BdV2Xf949rz9bf3z9tc1q31Vnbd/Pnaffr3DtkzTtHSe/vnYn+21COswHo/XvoTcHs+282w2c2216UvVwy8YD48b1jtJErcsXNdnt7PiOHb7sMtsG9r9jMdjVx+/fTcdo6p8NpuV2ilsN9Tnub/+AXg+XmRP2Ldv35SmqVqtlivLskyXl5el9XxxHO/UKyJJ4/HY/XxwcKA0TdXpdCRJh4eHWiwWkqROp6OTkxO37sePH3fqzZhMJpW9QlaWZW7YzT+e5W/rn/doNNLXr19L64XDd3meK45jdz6tVktpmpbWieNY/X6/VLaJHSa01+LDhw+l+p6dneno6Eha7Xc8HssYo729PSVJ4tbzFUVxZzuen58rSRJ33E6nU9rfZDJxyxqNhuI41u3trVtu3dzclLY7ODjQ9fW1tKq7fy0ajYbSNNXV1ZVarZbiONb5+bnktat/T/q+f/9eet5qtUrXMWw3AMDz9yJDmCTt7e2Vnr99+3brm5g/J8wGJ3+4Khxa2qYoCvezP3Q2GAxK6z0W/3iht2/flp6/fv269LxKOAT5O+zx5vO5JOnq6qq0/8VioXfv3mk+n5fCn1ahVauAcnBwIK3C1Hg8dqHZ7rdKGDB94QcyNrXh27dvNZ1O3fOLi4vSvRW2797enguInz9/dgH47OxMnz9/Lq1rGWM0GAzW/gPgD4N2u93SNgCA5+/FhjDbW2Hd3NzcO1wsFgsXzLb1TG1i31DtPrIsC1d5cjc3N6Xntmdqm21htUoYeKvs7+8riiKNRqNSW9rwc3t7667PcrnUYDBwAWcwGOjw8NBt0+l0ZIzReDx2c8GqbOst83vdjDGK4zhcpcSGoWazWeoFDNv3+vrahb9Pnz5pOp1quVxqOp3q06dPpXV9th6j0Uh5nms4HOri4sKV+72vAIC/w4sMYYeHhxqNRqVeksFg4Ia9/iS/N+b09LS0bJNtE/N34fem+OedJImOj4/dsna7reVyqV6v5wLQu3fvVBRFaeL5aDRy21R5+/ZtaR3/+D9+/FCSJC5MmIpPhP78+VOdTkfT6VRRFLmJ+t1uV1EUKcuyymG8N2/ehEXO+/fvNZ1O3T0wHA5LPVrytp/P52u9l7b9r66ulGVZZRg/OjrSYDBwYW+5+jMZNjA2Gg0lSaKDgwMlSeLuBfvBh6pePD8M+v9pODs7cz8DAP4OLzKEtVot10tiezDG43FpqCvkzwnb9AZ5XycnJxqNRm6fdkjtqe3t7blj+vPVJpOJFouFW/bx48e1IbtGo1EKQHbe0zZ2vpXdrx927bH9tvXDRZIkbj6UDTqLxcL1dhljSj1P/hDd/v6+ZrOZW+ZrtVrKsszdA9fX16W5bf79cXR0tHH+2cnJiRsqtA8bMjudjrIsc/dOHMeazWalwHh0dKSiKDb+ByD8FO/BwYE6nY76/X7pWoXXCQDw/EWmquvhN7169Uq/fv0Ki1Gz+Xyu/f39yt6mugyHQ11eXpZ6kNrttj5+/Kh+v6/lcqk4jpWmaelDDM+FX1criqK1sIWXg9c/ALt6kT1heD78OVLWYrFw870ajYaMMbq4uCj1CEUVf6OsDn5d5c0z2+UDDgCAl42esBfkOfaEaTW3yZ9zlWXZzn/iom62p85HL9jLxusfgF0RwgDgEfH6B2BXDEcCAADUgBAGAABQA0IYAABADQhhAAAANSCE4dmxf6A01Ov17vzydAAA/haEsBpEj/QX9x/DcDj8ra9Aegrfvn0r/fV6y//Kn13ZL+Le9j2R9+V/6XqVZrPpvtYJAIBNCGF3iKJo7Q3V/y5FX9W6jyU85p8Kcu12W8PhsFT21CHj4uJiLWzN53PFcVz739+az+eaTqcbv+cSAIBdEcLukKaprq6uSmUXFxcqiqIUguzP275/8necnJxosViExf8c245h2Pr27Zs+f/5cKqvD7e3t2h9nBQDgIV5sCAu/GHnTXKMPHz7o4uLCPbfDWv4XS0vS9+/fS1/ynOd5af9hr9Xt7W1pua/ZbK7Vyw4b2uE1Se4Lpu2+tx2z3W5vHXb0v/ja9nI1m01Np1P3BdXD4VBRFKkoCvcF3nmeK89z12MW1luruvv1suw+fZvC1mg00qdPn9xzv75hr6Q/XHh+fl5apuDLwjdddwX7sefX7XZVFEVp203nbVVdzyr+8exj07W17VY1T66q91IV+7D38qZyAMATM08giqKw6FmZzWZGkpnNZq5MksmyrLSeMcYURVFadzwemzRNTZZlJkkSt16SJGY8Hhvj7b8oitJzS5KJ47i0rd1XuF8rLA/rf9cx/WP4siwzklzdx+Px2nZhu8Rx7NY33jZpmhrjtdl4PHY/23r5qto8PC+z2r/fXlmWlbaL49g9z7JsrW394/vr2uf+uVjhMTeVh+0etmeSJO58wnvJF9a76prYY/jtG16vu9o7PPZsNivdF2maVt4n2N1zf/0D8Hy8yJ4wO/HbH/LKskyXl5el9bT6Amm/1+vs7EwfPnzQp0+fNJ1OtVwutVwuNZ1O9e7dO8nbv/1i6larpTiOS/Oozs7O3M9fv37VdDp1z/2fd3XXMSeTiSaTSbDV/yRJ4oZR7b/37Q2J41gnJyfSqs3CYdwfP354a/+PMab0HZF5nlfO+zo7Oyv1jvX7/dJ2BwcHur6+liSdnp7q+PjYLbN10qr3syiK0rafP38uXQtfURR3tkPY7v1+vzRcOZlM3Pk0Gg3Fcazb21u33Lq+vtbBwYF7niSJbm5upNX5Z1nmjuG3r71e9jqfn58rSZK1L0W3/N5bre4T/7748OHDixj2BoDn4EWGMEna29srPX/79u3GN5+PHz+6gGbDln1D/fHjh378+LH2xjcajUpDPP4XVIdev37tfu73+8qy7EFDQ/c55l1+/vwZFt2Lbd9Go1EavqwaJrPCsKVVGJxOp6WhSAVDfKPRqLTszZs3pechv40Gg0G4WFqF0fF4rDiOFVUMJ/vCe8lnh4/vuiZ7e3ulYe/pdKq3b9+65/7PWq1v7w0/8J6enuro6Ki0rmWMcUPL/hCmP7Tb7XZL2wAAns6LDWG258S6ublZm1tk2V4v+wk9G7YODg50dXWlq6srffz4sbRNmqbuE3T2sWnSfhh4+v2+jDHKsqzUO3KX+xzzqfnt22g0ZIxRURQaDAaVgWZT2Krq2Wm32zo4OHDnGP45i6qeJl/YRpt6CDudjowxGo/H2t/fDxc74b3ki+NY4/HYHWvbpH471yyKIqVpWrp2tlfMur6+dm1yeHio0Wik5XKpoii2XnNbj9FopDzPNRwOdXFx4crH43G4CQDgibzIEGbftPwwMBgMNvYg2F6vo6OjUiiy+7m4uND79+/Xyrf1YvnHOj4+XgsSquj98IXDWncd866J+Zs0Go21kNFsNtdCQVEUrpdruVxW/k2vcIjM7xmrClva0rPj9z75PWEHBwf6+vVr6bllh2g39cZtaqNtPWsfPnwotXuv11vr7bLb2+FQyz/e5eVlKaz5w6hHR0caDAbuGGH72vM6ODgo3Ud2wn3VPeGHQf8/H5uGZgEATyCcJPYY/oaJqXZCs31UTc722QnX4cRmBZPsrXD//mRpezxbXjWRPNwmnJhv6+Ovs+2Y2ybmh+XyztNOPLd1NsFxZrOZm6yepqkrt5Pfwzr5k+L951UT5MMPF1h28rl9pGnqPhRgVvvy66dgorq/rV8Hv438c7H7MRUT88N1bXtWtVUcx6Vl/vHCc/LrZYLr7dcnXO6X22MXRVG6jvI+RGGC9krTdO38cD9/w+sfgOchMv97U3pUr1690q9fv8Ji/KPyPNfXr183zqm7y3K5VBzHCm/F4XCo6+vrUq/Qv6rZbOr4+Lj0wYg4jlUUxVrvIJ43Xv8A7OpFDkfieTk/P68cjj09PV0b0vxXFUVRGva08wQJYADw76InDL/td3vC8L/5YuHkf3rB/k68/gHYFSEMAB4Rr38AdsVwJAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUIPIGGPCwt/16hXZDsDL9evXr7AIANY8SQgDAADAdnRZAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADV48hCW57miKCo9ms1muFqlXq/ntsnzPFz8ZIbD4Vqd5/O5tKpTaLlc3mv9cP+2PfI8d9tV8bcZDodaLpcaDofhagAA4C/wpCGs3W6r2+0qSRIZY2SMUVEUKopiY7DyQ8XJyYniOC4tf2pRFGkwGChNU1dnY4yOjo4URVG4unq9nqujv/7x8XHl+lX7v7i4UBRF6na74epOFEWlbSRVts1DQtlDtgEAAL/nyUJYr9fTdDqVJE0mE1feaDQ0Ho8lSd1uV8vl0i1bLpcaDAbu+Z9me6TSNNXJyUlp2WKxUJqmpbLhcKjRaCStAphvMpkoy7JS2ab9NxoNGWMqQ5VWPWSSdHh46Mr6/f5afR7Sfg/ZBgAA/L4nCWHL5dKFkzAoSNK7d+/cz//995/7eVMI+RPyPFdRFFIQdnxfvnwpPbfhpeoctQpK1i77Pz4+DotK9vf3S6E1rM9D2u8h2wAAgN/3JCHs58+f7ue9vb3SMq16fqyLiwtpNdxmRVFUOZfKzodqt9ul8nBOluXPvRoOh+55uL0knZ2duZ9fv35dWmY1Gg3Xg+UPpX748MFbq8yu7++/1Wp5a/y/TqdTuazT6bif4zh259hoNFzQ29R+7Xa71DZ+u27axj63Dxv8wnb229Eep+q6AQCAdU8Swm5vb8OirZbLpWazmXtujFkbDux2u27Ibjqdugns8/lccRy7eWdJkrhhv36/ryRJJK/Xyj7fxg+Jm9zc3IRFWy0Wi7DoXsLhTj/wbGq/PM81nU7dXDJJGo1Gms/nG7exQSuOYxljlKap6y3r9XqunW2vHgAAeJgnCWFv3rwJizZqNps7hR47j8yyQe/bt2+SpI8fP0qrAFUUxdqnDNM0Vb/f12QyKc1Ru0v4ScboHp/ufGzGmFI7jEYj9Xq9je3X6XQqA622BM3z83NJ0sHBgeT1ZOZ5rkajoel0qna7rUajUWrHyWSy8VgAAGDdk4Qwf0jt+vq6tEyrnhvLhqeHsvsaDAaKosjNRQt746qGRX1+PfwA1+/3S71QaZpqsVjo/fv3ruzq6sr9vIkNNQr2vwv75yjkBSs7D82e7zbz+bw09Bi2jc9er9FopGj1SU6tev5OTk6Upqmm06miDZ9uBQAAu3mSECbJfTKwKiTY3hYFk9cfwvbohH9Swp9HtQu/HrZ3bZtWq+WGNqvO0bJBxZ9Ev2n/20KN/wEGreaa7TK0GkWRjo6O1oYzN7Fh1f+zIsYY1z4nJycyq2Hhbrd770AJAAD+58lCmD8fy5/APZ/PXe+KPyfJt7zHHyG1k+JHo5HrLRoOhw8KB3ae02g02un4k8nEzZcKhyht75MNg41Gw51v1f57vd7WHjU79Ggtl0s33ytk28+uf3BwUOp9rGK3sT18/ry7PM+V57l6vZ4Liv4HDcTEfAAA7s88sdlsZiSVHkmShKsZY4xJksRIMnEcG2OMSdN0bTv/eVEUxhhjxuNxqTzLMmOMMVmWlcpns1npeJuE29nHJuHxteUcjXee/mM8HoerOVmWmdlstnYce55W2H7++nEcl45r2y7cxlRcszRNjVldD/+a+Me3+7HrAgCA7SKz6zgVAAAAHs2TDUcCAABgM0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFCDyBhjwkKURVGkKIrCYgAA8If9+vUrLPprEcJ28OrVq3/qogMA8Df6196PGY4EAACoASEMAACgBoSwJ7ZcLt2csvCR53lp3Xa7rXa7XSrD4xoOh2o2m2HxH2HvhfC642XK8/xJ5ppGUaThcBgWA3iGCGFPrNFoyBijNE0Vx7GMMe55t9t1L5btdlvT6TTcHI9oOBxqMBiExX/EcrlUHMdhMV6oPM/V7XbD4kdhjFG/3w+LATxDhLCanJycSJJOT08lSZPJREmSBGv9ux6rx28+n2/9X3+e567nqd/vK8uycJU/otFoqCiKsLg2y+VSvV4vLP4r9Xo9LZfLsPjBHuveDPlt3ul0NB6Pw1WexGO3D4DHQwirUZIkz+qN+U8ZDodaLBZh8YMcHR2FRSVP1dvwt/tXAth8PtdoNAqLH+wp2+Up973JY7cPgMdFCKvRYrG4c4iq3W67OWT+i7idT1K1bD6fu/L5fF6agxRut41/7LB3YDgclvbj/0/bzrvy58PZ+vV6PQ0GAxVFocibu9JsNjfuL5xXZ88niiIVRaHBYLBxG62CmP05XO7Xzer1em5ZeN6+ZrNZaof5fC7dY3tVnJvdh19mz9fu1+7TP46/nlbXrtfrla63Xd5sNjWdTjUajUrHDPn7Dnsb/XsjnGNXdez5fF66L6vuZb8twnbz29keL89z7e/vS5LiOC5t499Pft17vZ7a7XapLv6UgNFopOl0qmjD3L3w98eeh20PWwe/vtqhzXc57yi4x20723PN87w07zBsn/B3LLxfw98DAH+AwZ2iKAqL7i1NUxPHsXueZZmRZLIsc2VJkpgkSUrPZ7OZe+6vL8mMx2NjjDHj8dhIMkVRGGNM6TjhemmaumVhnXxJkrh1i6Io7SfLslI90zR1x7fnJcntO6xflmVrbeE/j+N47di2Hez+/XX9Ngz59Tbe9mHdrDRNS+v7dfHFcezO07dt+7Adi6IonXdVO4XHtu0wm81K6/rXMkkSVze7fXit/etbxa9nWK8kSUptHsfx1mPbMnvP+PuzP/vXxJ6bPUaWZRt/T8J2MKv62Od+m9v71K9LeD+laVq6t0Pb2iXcNry3wjb3z91UnMu23zO/ncNz9esY7tNU/M4URbH1XgCek8d4P35OCGE7eIyL7r8B2Ef4wue/ufgvqP4jfIPwQ499od0UHPwXbv/hv0Ab74V7E3mhyPKPGYaq8I0gXO6zdfLDQ9W5WOEbSkgVIWxb3cK2kRcOQlXHDrf1t/cDgQmunf/YFNKKolhrd+Nd120hKzzvcLkvfPP3Vd0b4XmF+w6PHbZ5GFZMEBpjL/D6j6p92efhw7+ftgWlcPkmVb934bbhvsN2CZfbdrTX2P/Z8n/Pwv2ZimsRto+pOG6WZWuvAcBz9Rjvx88Jw5G/yR+WqRpO8PmfjjTGuMn5VX7+/Lm2vjFGk8lE8oYpJGk2m5W2PT4+dsMedh2thj9ns9naPhuNRmn729vb0nPfpgm+dvjxoWxdjTGlDyj8zj7vyx4rbJ9d56/dd/vr62tlWba2fqfTkVaT+ZvNphsWOz8/V6vVctvbe+/r16+P+oGD6+vrsMipujfs/XNzcxMuerC9vT33c1EUKopirZ2q3N7eKkmStXW3/a7dx7bfu8e06b7/3d8zrT4UEMexG4a9vr5eew0A8GcQwn7TZDIpvdjbkPS7Xr9+raIoKl9w5/O5m1dV9VH0TqcjY4x7k7BzaJrNpr5//x6sve7NmzfSljcCSZX7eegLebvdVpqmlW+sjUZjaz0ek61/OF9nV/fdfm9vT5eXl2FxydHRkb5+/RoWuw83GGNKwewx7O3tbQyOVtU5vn37Nix6sOvra3ffxnGsHz9+hKtUevPmzZP9qZe7fu+ewmP+nvmOj481GAw0n8/14cOHcDGAP4QQ9kw1Gg0lSaKDg4NSuT959ufPn1LFC7V982q1WqX/rR8dHbkXXms4HK6FnFarpTiOK4/daDSUpmlpP8vlUtPpVF++fCmtvwv7v3G/Dv6b6OHhoabTaWlydZ7nayHATvzexE5avkuapm4ys3WfCcv32f7Tp09r5zYPPkjR6XRUFIXa7bY+ffrkyrXqIbLuCnObLJfLtQnonz59UlEUpXrbetleFP8c8zxXHMeuB++hbD2Wy6VGo5ELn58/f1a32y1dv6o2HQ6H7t4Ne6Sr1r9L+GEEa9PvnVa9zZatv98brQ1tHnrs3zMF5+Nfx9+9bgB+Qzg+iXW/MwZdNbfLn6Nk+fO1/Hkl4XwYO3fDXz/15pvNZrO1uUb+fI9wWTinyRce2+cf0z9GWO5PPtaqfv68HTvPyV/H7sO2Q9XysB6b5vHYdkpXc8v8/VTVzd8mLPdtqo/ZsH14H4Rzduyj6jzCuUZWWAf7s3/d7Lwhf11T8QGFUFjf8Pj+Mfx93HXsqja3Zf664e9I1X6sbWX2YYLrYufz+esUwQcFqmz7vQvbzO7f8ts8PHbYLvZcwvO2v2dhO5uKa2b3ET63xuPx1t9/4Dn6nffj5ygyVWNAKPnXvrUdeE7y1V+P56XozxoOh/r06dOjDG8Cf8q/9n7McCQAvECXl5cEMKBmhDAAtRkOh+5bDaLgj5Hi8fmf5n6sDxEBeDiGI3fwr3V/AgDwN/rX3o8JYTt49YoOQwAAngNCGAAAAH4LXTwAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADX4P43Hb4EcOT7lAAAAAElFTkSuQmCC" alt="" width="609" height="295" vspace="0" hspace="0" border="0" style="width:609px;height:295px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the postmarketing experience, the most commonly reported adverse reactions observed when pregabalin was taken in overdose included somnolence, confusional state, agitation, and restlessness. Seizures were also reported.</p><p>In rare occasions, cases of coma have been reported.</p><p>Treatment of pregabalin overdose should include general supportive measures and may include haemodialysis if necessary (see section 4.2 Table 1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-epileptics, other anti-epileptics. ATC code: N02BF02</p><p>The active substance, pregabalin, is a gamma-aminobutyric acid analogue [(S)-3-(aminomethyl)-5- methylhexanoic acid].</p><p><u>Mechanism of action</u></p><p>Pregabalin binds to an auxiliary subunit (&alpha;2-&delta; protein) of voltage-gated calcium channels in the central nervous system.</p><p><u>Clinical efficacy and safety</u></p><p><em>Neuropathic pain</em></p><p>Efficacy has been shown in trials in diabetic neuropathy, post herpetic neuralgia and spinal cord injury. Efficacy has not been studied in other models of neuropathic pain.</p><p>Pregabalin has been studied in 10 controlled clinical trials of up to 13 weeks with twice a day dosing (BID) and up to 8 weeks with three times a day (TID) dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar.</p><p>In clinical trials up to 12 weeks for both peripheral and central neuropathic pain, a reduction in pain was seen by Week 1 and was maintained throughout the treatment period.</p><p>In controlled clinical trials in peripheral neuropathic pain 35% of the pregabalin treated patients and 18% of the patients on placebo had a 50% improvement in pain score. For patients not experiencing somnolence, such an improvement was observed in 33% of patients treated with pregabalin and 18% of patients on placebo. For patients who experienced somnolence the responder rates were 48% on pregabalin and 16% on placebo.</p><p>In the controlled clinical trial in central neuropathic pain 22% of the pregabalin treated patients and 7% of the patients on placebo had a 50% improvement in pain score.</p><p><em>Epilepsy</em></p><p>Adjunctive Treatment</p><p>Pregabalin has been studied in 3 controlled clinical trials of 12 week duration with either BID or TID dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar.</p><p>A reduction in seizure frequency was observed by Week 1.</p><p><u>Paediatric population</u></p><p>The efficacy and safety of pregabalin as adjunctive treatment for epilepsy in paediatric patients below the age of 12 and adolescents has not been established. The adverse events observed in a pharmacokinetic and tolerability study that enrolled patients from 3 months to 16 years of age (n=65) with partial onset seizures were similar to those observed in adults. Results of a 12-week placebo-controlled study of 295 paediatric patients aged 4 to 16 years and a 14 day placebo controlled study of 175 paediatric patients aged 1 month to younger than 4 years of age performed to evaluate the efficacy and safety of pregabalin as adjunctive therapy for the treatment of partial onset seizures and a 1 year open label safety study in 54 paediatric patients from 3 months to 16 years of age with epilepsy indicate that the adverse events of pyrexia and upper respiratory infections were observed more frequently than in adult studies of patients with epilepsy (see sections 4.2, 4.8 and 5.2).</p><p>In the 12-week placebo-controlled study, paediatric patients (4 to 16 years of age) were assigned to pregabalin</p><p>2.5 mg/kg/day (maximum, 150 mg/day), pregabalin 10 mg/kg/day (maximum, 600 mg/day), or placebo. The percentage of subjects with at least a 50% reduction in partial onset seizures as compared to baseline was 40.6% of subjects treated with pregabalin 10 mg/kg/day (p=0.0068 versus placebo), 29.1% of subjects treated with pregabalin 2.5 mg/kg/day (p=0.2600 versus placebo) and 22.6% of those receiving placebo.</p><p>In the 14-day placebo-controlled study, paediatric patients (1 month to younger than 4 years of age) were assigned to pregabalin 7 mg/kg/day, pregabalin 14 mg/kg/day, or placebo. Median 24-hour seizure frequencies at baseline and at the final visit were 4.7 and 3.8 for pregabalin 7 mg/kg/day, 5.4 and 1.4 for pregabalin 14 mg/kg/day, and 2.9 and 2.3 for placebo, respectively. Pregabalin 14 mg/kg/day significantly reduced the log- transformed partial onset seizure frequency versus placebo (p=0.0223); pregabalin 7 mg/kg/day did not show improvement relative to placebo.</p><p><u>Monotherapy (newly diagnosed patients)</u></p><p>Pregabalin has been studied in 1 controlled clinical trial of 56 week duration with BID dosing. Pregabalin did not achieve non-inferiority to lamotrigine based on the 6-month seizure freedom endpoint. Pregabalin and lamotrigine were similarly safe and well tolerated.</p><p><u>Generalised Anxiety Disorder</u></p><p>Pregabalin has been studied in 6 controlled trials of 4-6 week duration, an elderly study of 8 week duration and a long-term relapse prevention study with a double-blind relapse prevention phase of 6 months duration.</p><p>Relief of the symptoms of GAD as reflected by the Hamilton Anxiety Rating Scale (HAM-A) was observed by Week 1.</p><p>In controlled clinical trials (4-8 week duration) 52% of the pregabalin treated patients and 38% of the patients on placebo had at least a 50% improvement in HAM-A total score from baseline to endpoint.</p><p>In controlled trials, a higher proportion of patients treated with pregabalin reported blurred vision than did patients treated with placebo which resolved in a majority of cases with continued dosing. Ophthalmologic testing (including visual acuity testing, formal visual field testing and dilated funduscopic examination) was conducted in over 3600 patients within controlled clinical trials. In these patients, visual acuity was reduced in 6.5% of patients treated with pregabalin, and 4.8% of placebo-treated patients. Visual field changes were detected in 12.4% of pregabalin-treated, and 11.7% of placebo-treated patients. Funduscopic changes were observed in 1.7% of pregabalin-treated and 2.1% of placebo-treated patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregabalin steady-state pharmacokinetics are similar in healthy volunteers, patients with epilepsy receiving anti- epileptic drugs and patients with chronic pain.</p><p><u>Absorption</u></p><p>Pregabalin is rapidly absorbed when administered in the fasted state, with peak plasma concentrations occurring within 1 hour following both single and multiple dose administration. Pregabalin oral bioavailability is estimated to be &ge; 90% and is independent of dose. Following repeated administration, steady state is achieved within 24 to 48 hours. The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately 25-30% and a delay in tmax to approximately 2.5 hours. However, administration of pregabalin with food has no clinically significant effect on the extent of pregabalin absorption.</p><p><u>Distribution</u></p><p>In preclinical studies, pregabalin has been shown to cross the blood brain barrier in mice, rats, and monkeys. Pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats. In humans, the apparent volume of distribution of pregabalin following oral administration is approximately 0.56 l/kg. Pregabalin is not bound to plasma proteins.</p><p><u>Biotransformation</u></p><p>Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabelled pregabalin, approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin. The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. In preclinical studies, there was no indication of racemisation of pregabalin S-enantiomer to the R-enantiomer.</p><p><u>Elimination</u></p><p>Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug.</p><p>Pregabalin mean elimination half-life is 6.3 hours. Pregabalin plasma clearance and renal clearance are directly proportional to creatinine clearance (see section 5.2 Renal impairment).</p><p>Dose adjustment in patients with reduced renal function or undergoing haemodialysis is necessary (see section 4.2 Table 1).</p><p><u>Linearity/non-linearity</u></p><p>Pregabalin pharmacokinetics are linear over the recommended daily dose range. Inter-subject pharmacokinetic variability for pregabalin is low (&lt; 20%). Multiple dose pharmacokinetics are predictable from single-dose data. Therefore, there is no need for routine monitoring of plasma concentrations of pregabalin.</p><p><u>Gender</u></p><p>Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of pregabalin.</p><p><u>Renal impairment</u></p><p>Pregabalin clearance is directly proportional to creatinine clearance. In addition, pregabalin is effectively removed from plasma by haemodialysis (following a 4 hour haemodialysis treatment plasma pregabalin concentrations are reduced by approximately 50%). Because renal elimination is the major elimination pathway, dose reduction in patients with renal impairment and dose supplementation following haemodialysis is necessary (see section 4.2 Table 1).</p><p><u>Hepatic impairment</u></p><p>No specific pharmacokinetic studies were carried out in patients with impaired liver function. Since pregabalin does not undergo significant metabolism and is excreted predominantly as unchanged drug in the urine, impaired liver function would not be expected to significantly alter pregabalin plasma concentrations.</p><p><u>Paediatric population</u></p><p>Pregabalin pharmacokinetics were evaluated in paediatric patients with epilepsy (age groups: 1 to 23 months, 2 to 6 years, 7 to 11 years and 12 to 16 years) at dose levels of 2.5, 5, 10 and 15 mg/kg/day in a pharmacokinetic and tolerability study.</p><p>After oral administration of pregabalin in paediatric patients in the fasted state, in general, time to reach peak plasma concentration was similar across the entire age group and occurred 0.5 hours to 2 hours postdose.</p><p>Pregabalin Cmax and AUC parameters increased in a linear manner with increasing dose within each age group. The AUC was lower by 30% in paediatric patients below a weight of 30 kg due to an increased body weight adjusted clearance of 43% for these patients in comparison to patients weighing &ge;30 kg.</p><p>Pregabalin terminal half-life averaged about 3 to 4 hours in paediatric patients up to 6 years of age, and 4 to 6 hours in those 7 years of age and older.</p><p>Population pharmacokinetic analysis showed that creatinine clearance was a significant covariate of pregabalin oral clearance, body weight was a significant covariate of pregabalin apparent oral volume of distribution, and these relationships were similar in paediatric and adult patients.</p><p>Pregabalin pharmacokinetics in patients younger than 3 months old have not been studied (see sections 4.2, 4.8 and 5.1).</p><p><u>Elderly</u></p><p>Pregabalin clearance tends to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with decreases in creatinine clearance associated with increasing age. Reduction of pregabalin dose may be required in patients who have age related compromised renal function (see section 4.2 Table 1).</p><p><u>Breast-feeding mothers</u></p><p>The pharmacokinetics of 150 mg pregabalin given every 12 hours (300 mg daily dose) was evaluated in 10 lactating women who were at least 12 weeks postpartum. Lactation had little to no influence on pregabalin pharmacokinetics. Pregabalin was excreted into breast milk with average steady-state concentrations approximately 76% of those in maternal plasma. The estimated infant dose from breast milk (assuming mean milk consumption of 150 ml/kg/day) of women receiving 300 mg/day or the maximum dose of 600 mg/day would be 0.31 or 0.62 mg/kg/day, respectively. These estimated doses are approximately 7% of the total daily maternal dose on a mg/kg basis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In conventional safety pharmacology studies in animals, pregabalin was well-tolerated at clinically relevant doses. In repeated dose toxicity studies in rats and monkeys CNS effects were observed, including hypoactivity, hyperactivity and ataxia. An increased incidence of retinal atrophy commonly observed in aged albino rats was seen after long-term exposure to pregabalin at exposures &ge; 5 times the mean human exposure at the maximum recommended clinical dose.</p><p>Pregabalin was not teratogenic in mice, rats or rabbits. Foetal toxicity in rats and rabbits occurred only at exposures sufficiently above human exposure. In prenatal/postnatal toxicity studies, pregabalin induced offspring developmental toxicity in rats at exposures &gt; 2 times the maximum recommended human exposure.</p><p>Adverse effects on fertility in male and female rats were only observed at exposures sufficiently in excess of therapeutic exposure. Adverse effects on male reproductive organs and sperm parameters were reversible and occurred only at exposures sufficiently in excess of therapeutic exposure or were associated with spontaneous degenerative processes in male reproductive organs in the rat. Therefore, the effects were considered of little or no clinical relevance.</p><p>Pregabalin is not genotoxic based on results of a battery of in vitro and in vivo tests.</p><p>Two-year carcinogenicity studies with pregabalin were conducted in rats and mice. No tumours were observed in rats at exposures up to 24 times the mean human exposure at the maximum recommended clinical dose of 600 mg/day. In mice, no increased incidence of tumours was found at exposures similar to the mean human exposure, but an increased incidence of hemangiosarcoma was observed at higher exposures. The non- genotoxic mechanism of pregabalin-induced tumour formation in mice involves platelet changes and associated endothelial cell proliferation. These platelet changes were not present in rats or in humans based on short-term and limited long-term clinical data. There is no evidence to suggest an associated risk to humans.</p><p>In juvenile rats the types of toxicity do not differ qualitatively from those observed in adult rats. However, juvenile rats are more sensitive. At therapeutic exposures, there was evidence of CNS clinical signs of hyperactivity and bruxism and some changes in growth (transient body weight gain suppression). Effects on the oestrus cycle were observed at 5-fold the human therapeutic exposure. Reduced acoustic startle response was observed in juvenile rats 1-2 weeks after exposure at &gt; 2 times the human therapeutic exposure. Nine weeks after exposure, this effect was no longer observable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline cellulose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydroxypropyl Cellulose-low Substituted</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stearic acid</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The immediate packaging material is PVDC/ALU blisters. Pack size:</p><p>40 hard capsules.</p><p>60 hard capsules.</p><p>500 hard capsules</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Middle East Pharmaceutical Industries Co. Ltd (Avalon-Pharma)
2nd industrial City, P.O.Box 4180 Riyadh 11491, Kingdom of Saudi Arabia
Tel: 920010564, Fax: +966 (11) 2654723
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>